SPOTLIGHT: Developers end animal studies on toxicity

A combo act featuring a slate of top European companies and clinical research organizations are bringing a close to an 80-year era of animal tests for acute toxicity. New methods that don't depend on rodents are better and a lot less time consuming. That's a victory--the first big one--for the UK's National Centre for the Replacement, Refinement and Reduction of Animals in Research. Report

Suggested Articles

A month after scoring $1.6 billion from the U.S. government, Novavax is posting the first human data from its COVID-19 vaccine.

CureVac named a permanent CEO, Franz-Werner Haas, and signed Novartis alum, Igor Splawski, Ph.D. as its new top scientist.

J&J studied the drug in midphase obesity clinical trials, but Merck sees it as a potential treatment for nonalcoholic steatohepatitis.